Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.256 USD | +2.36% | +2.40% | -61.62% |
Valuation
Fiscal Period: December | 2023 |
---|---|
Capitalization 1 | 7.935 |
Enterprise Value (EV) 1 | 11.37 |
P/E ratio | -0.08 x |
Yield | - |
Capitalization / Revenue | 610 x |
EV / Revenue | 875 x |
EV / EBITDA | -0.33 x |
EV / FCF | -3,503,334 x |
FCF Yield | -0% |
Price to Book | -0.32 x |
Nbr of stocks (in thousands) | 11,897 |
Reference price 2 | 0.6670 |
Announcement Date | 4/16/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Net sales 1 | 0.692 | 0.013 |
EBITDA 1 | -37.34 | -34.9 |
EBIT 1 | -37.5 | -35.27 |
Operating Margin | -5,419.51% | -271,276.92% |
Earnings before Tax (EBT) 1 | -37.43 | -51.98 |
Net income 1 | -38.01 | -48.07 |
Net margin | -5,493.21% | -369,784.62% |
EPS 2 | -13.13 | -7.987 |
Free Cash Flow | - | -3.245 |
FCF margin | - | -24,963.46% |
FCF Conversion (EBITDA) | - | - |
FCF Conversion (Net income) | - | - |
Dividend per Share | - | - |
Announcement Date | 4/16/24 | 4/16/24 |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Net Debt 1 | - | 3.43 |
Net Cash position 1 | 0.66 | - |
Leverage (Debt/EBITDA) | - | -0.0984 x |
Free Cash Flow | - | -3.25 |
ROE (net income / shareholders' equity) | - | 377% |
ROA (Net income/ Total Assets) | - | -181% |
Assets 1 | - | 26.55 |
Book Value Per Share 2 | -0.3800 | -2.050 |
Cash Flow per Share 2 | 0.8300 | 0.4100 |
Capex | - | - |
Capex / Sales | - | - |
Announcement Date | 4/16/24 | 4/16/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-61.62% | 10.91M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- ADXS Stock
- Financials Ayala Pharmaceuticals, Inc.